MedPath

A retrospective analysis of the efficacy and safety of complete surgery for advanced ovarian, fallopian tubal, primary peritneal, uterus corpus cancer

Not Applicable
Recruiting
Conditions
ovarian, fallopian tubal, primary peritneal, uterus corpus cancer
Registration Number
JPRN-UMIN000013079
Lead Sponsor
School of Medicine, Chiba University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Female
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

1)Patients who have a history of hypersensitivity to gemcitabine and irinotecan. 2)Patients with active infection 3)Patients with severe complications (Heart disease, uncontrolleddiabetes, malignant hypertension, or bleeding tendency) 4)Patients with other cancer within the past 5 years 5)Patients with myocardial infarction within 6 months or angina attack. 6)Patients who are inappropriate to enter this study with any safety reasons,judged by the treating physician.

Study & Design

Study Type
Interventional,observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Progression free survival,toxicity
Secondary Outcome Measures
NameTimeMethod
overall survival
© Copyright 2025. All Rights Reserved by MedPath